Unlocking the power of RNA therapeutics

We are a RNA therapeutics company using our proprietary, next-generation silicon stabilized hybrid lipid nanoparticles (sshLNP) to address unmet medical needs in the therapeutically neglected field of Genetic Skeletal Disorders. Built upon a decade of research and patented technological innovation, our BIO-COURIER® platform is changing the way therapeutic molecules target disease helping to make tomorrow’s medicines a reality.

Company

Our in-house pipeline is focused on rare Genetic Skeletal Disorders which account for 5% of all birth defects and are an important cause of disability worldwide, yet very few have personalised treatments. In partnership, we are also developing the world’s 1st topical RNA interference therapy in rare ophthalmic disease.

Pipeline

Team

Founded and led by an authority in nanoparticle science for therapeutics, Dr Suzanne Saffie-Siebert Ph.D., our expert team and academic partners are focused on the translation of cutting-edge research into safe, effective, and accessible drugs for currently untreatable diseases.

Meet The Team

Technology

Our proprietary BIO-COURIER technologies include a next-generation, non-viral, silicon stabilized lipid hybrid nanoparticle (sshLNP) to improve the stability, storage, delivery, and immunogenicity of RNA therapeutics.

More

Why Sisaf?

We are in the midst of a RNA therapeutic revolution, the likes of which have not been seen since the advent of recombinant protein technology almost 50 years ago. SiSaf is at the forefront of stabilizing, storing, and delivering RNA therapeutics, ultimately increasing their access to the global population.

More

News

SiSaf exercises its option under licencing agreement on gene therapy for rare bone disease

More

SiSaf Ltd utilizes Intoolab’s Tzager AI Platform

More

SiSaf Ltd Announces US$13.2 Million Series B Financing

More

Non-invasive ocular siRNA delivery induces effective gene silencing in corneal epithelium

More

SiSaf announces licencing agreement to develop gene therapy for rare bone disease

More

SiSaf Makes Its Bio-Courier® Technology Available for COVID-19 Vaccine Research

More

SiSaf Establishes Strategic Partnership with Avellino Labs

More

SiSaf Strengthens it’s Leadership Team

More

SiSaf Ltd Appoints Former Oxford BioMedica Executive

More

Croda Invests in SiSaf’s Novel Bio-Courier Technology

More

UK based biopharmaceutical company SiSaf closes $4.3 million interim funding round

More

SiSaf’s Chairwoman and Chief Executive Officer, Suzanne Saffie-Siebert featured on BBC Radio 4’s ‘In Business’

More

Next-gen silicon nanotechnology drug delivery company SiSaf raises $3.5 million in Series A Funding

More

Silicon Valley Investors Lead Funding Round in SiSaf

More

SiSaf Releases latest Clinical Data Showing a 95% Reduction in Acne

More